# Oxford Cancer Analytics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oxford-cancer-analytics

- Industry: Biotechnology
- Headquarters: Oxford, UK
- Website: www.oxcan.co.uk/
- Total disclosed funding: $16M
- Latest round: Series A (Nov 19, 2024)
- Investors on record: 13

## About

Based in Oxford, UK, and founded in 2020 by co-founders Dr. Peter Jianrui Liu (CEO) and Dr. Andreas Halner (COO), Oxford Cancer Analytics Ltd. operates as a developer of blood-based diagnostic tests for healthcare providers, focusing on early cancer detection using advanced proteomics and artificial intelligence. In January 2025, Oxford Cancer Analytics Ltd. raised GBP 8.9 million in series A funding co-led by new investors We Venture Capital and Cross-Border Impact Ventures, with participation from other new investors DigitalDx Ventures, Macmillan Cancer Support, Aurelium Ventures, and OKG Capital. Returning investors Eka Ventures, Civilization Ventures, and individual investors also participated in the round.

Oxford Cancer Analytics specializes in the development of advanced blood tests intended for early cancer detection, leveraging improved proteomics and artificial intelligence. Their core product offerings include a new generation of blood-based liquid biopsy tests intended to identify cancer biomarkers, specifically proteins indicative of lung cancer. These products are intended for use in clinical settings, targeting healthcare providers and institutions involved in cancer diagnostics and patient care. The geographical market for these products primarily includes North America and Europe, focusing on institutions involved in oncological research and treatment.

The revenue model for OXcan is primarily based on partnerships with healthcare institutions and diagnostic laboratories that utilize their liquid biopsy tests. Transactions may occur through direct agreements with hospitals and clinics, where OXcan's products are integrated into their diagnostic services. The company’s revenue structure involves both direct sales to healthcare providers and collaborations with research institutions that require access to their advanced cancer detection technologies. OXcan’s flagship products, based on their proprietary DEcancer platform, are expected to be utilized in a variety of clinical applications, establishing a recurring revenue stream as these institutions adopt the technology for routine cancer screenings and diagnostics.

OXcan has targeted entry into the North American and European markets, with strategies in place to establish partnerships in these regions by the end of 2025.

## Funding rounds

- Series A, Nov 19, 2024, $11M — Macmillan Cancer Support, Civilization Ventures, DigitalDx Ventures, Eka Ventures, Cross-Border Impact Ventures, OKG Capital, We Venture Capital, Aurelium Ventures
- Seed, Jan 11, 2023, $1.8M — Oxford Technology Management, The Francis Crick Institute, Civilization Ventures, MegaRobo, Cancer Research Horizons
- Seed, Aug 22, 2022, $3.7M — Oxford Technology Management, MegaRobo, Eka Ventures, LifeArc

## Investors

- Oxford Technology Management (https://capitalatlas.ai/funds/oxford-technology-management) — Seed
- MegaRobo — Seed
- Eka Ventures (https://capitalatlas.ai/funds/eka-ventures) — Seed, Series A
- LifeArc (https://capitalatlas.ai/funds/lifearc) — Seed
- The Francis Crick Institute — Seed
- Civilization Ventures (https://capitalatlas.ai/funds/civilization-ventures) — Seed, Series A
- Cancer Research Horizons (https://capitalatlas.ai/funds/cancer-research-horizons) — Seed
- Macmillan Cancer Support — Series A
- DigitalDx Ventures (https://capitalatlas.ai/funds/digitaldx-ventures) — Series A
- Cross-Border Impact Ventures (https://capitalatlas.ai/funds/cross-border-impact-ventures) — Series A
- OKG Capital (https://capitalatlas.ai/funds/okg-capital) — Series A
- We Venture Capital (https://capitalatlas.ai/funds/we-venture-capital) — Series A
- Aurelium Ventures — Series A